“WHAT’S PAST IS PROLOGUE” Big Pharma’s Track Record Is A Vast Departure From Its Rhetoric: Part II

In advance of the hearing on January 29, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is rolling out a new blog series on what lawmakers can expect to hear from pharmaceutical companies.

Yesterday, we looked at AbbVie, Celgene and Mallinckrodt.

Today, we will look at the rhetoric and track records of Eli Lilly, Novo Nordisk and Sanofi – the three largest makers of insulin in the world, controlling 99 percent of the marketplace and facing no generic competitor to drive down prices.

As The Washington Post reported in “Life, Death And Insulin,” these three companies “appear to have increased [prices] in lockstep over a number of years, prompting allegations of price fixing.” Between 1996 and 2006, the price of insulin increased by 700 percent. In the face of rising prices, one-quarter of patients with Type 1 or Type 2 diabetes have turned to rationing their insulin, some with deadly consequences.


Eli Lilly’s Rhetoric:

Eli Lilly’s Record:


Novo Nordisk’s Rhetoric:

Novo Nordisk’s Record:


Sanofi’s Rhetoric:

Sanofi’s Record:

Stay tuned for another blog tomorrow comparing Big Pharma’s rhetoric with its track record.

CLICK HERE to read Big Pharma’s Track Record Is A Far Departure From Its Rhetoric: Part I.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.